Fruquintinib

Fruquintinib is an oral inhibitor of vascular endothelial growth factor receptor (“VEGFR”) 1/2/3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis.

Fruquintinib was approved by the China National Medical Products Administration (NMPA) in September 2018 under the brand name ELUNATE^®. Fruquintinib (FRUZAQLA® outside China) was approved by the US FDA in November 2023, by the European Commission in June 2024 and in 10 other countries.

HUTCHMED has licensed the rights of fruquintinib to Takeda on a worldwide basis excluding mainland China, Hong Kong and Macau where the rights have been licensed to Eli Lilly and Company.

Surufatinib

Surufatinib is a novel, oral angio-immuno kinase inhibitor that inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages.

Surufatinib has been approved by the China National Medical Products Administration (NMPA) and is marketed in China under the brand name SULANDA^®.

HUTCHMED currently retains all rights to surufatinib worldwide.

Savolitinib

Savolitinib is an oral selective MET TKI that blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations) or gene amplification.

Savolitinib has been approved by the China National Medical Products Administration (NMPA) and is marketed in China under the brand name ORPATHYS^®.

In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing agreement to jointly develop and commercialize savolitinib. Joint development in China is led by HUTCHMED, while AstraZeneca leads development outside of China. HUTCHMED is responsible for the marketing authorization, manufacturing and supply of savolitinib in China. AstraZeneca is responsible for the commercialization of savolitinib in China and worldwide.